Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

Phospho-tau217 has emerged as an excellent marker of the presence of amyloid pathology in the brain, but for markers of neurofibrillary tangles, fragments of tau’s microtubule binding region have a ...

At this year’s Alzheimer’s Association International Conference, held July 27-31 in Toronto, scientists introduced a plethora of new assays for biomarkers that could improve diagnosis and tracking of ...

Lithium is one of the oldest drugs in psychiatric medicine, commonly prescribed for bipolar disorder. Now, a study in the August 6 Nature lays out a new case for the potential use of this metal ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Statins do not help prevent Alzheimer’s disease, but another cholesterol-controlling drug just might. Obicetrapib blocks cholesteryl esters being transferred from the “good” high-density lipoproteins ...

Computational biology has put the human brain vasculature in its crosshairs. On July 23 in Neuron, scientists led by Andrew Yang, University of California, San Francisco, report a multiomic approach ...

The investigational drug obicetrapib blocks the transfer of cholesteryl esters from high- to low-density lipoprotein. In a cardiovascular disease trial, it reduced plasma p-tau217.

AAV-sTREM2 5xFAD mice were created to study the long-term effects of soluble TREM2 (sTREM2) in the context of amyloidosis. To generate this model, AAV carrying cDNA encoding EGFP- and FLAG-tagged ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...